- Home
- DAWN vs HBNC Comparison
DAWN vs HBNC Comparison
Compare DAWN & HBNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- HBNC
- Stock Information
- Founded
- DAWN 2018
- HBNC 1873
- Country
- DAWN United States
- HBNC United States
- Employees
- DAWN N/A
- HBNC N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- HBNC Major Banks
- Sector
- DAWN Health Care
- HBNC Finance
- Exchange
- DAWN Nasdaq
- HBNC Nasdaq
- Market Cap
- DAWN 624.8M
- HBNC 706.4M
- IPO Year
- DAWN 2021
- HBNC N/A
- Fundamental
- Price
- DAWN $7.19
- HBNC $16.22
- Analyst Decision
- DAWN Strong Buy
- HBNC Buy
- Analyst Count
- DAWN 7
- HBNC 3
- Target Price
- DAWN $27.86
- HBNC $19.67
- AVG Volume (30 Days)
- DAWN 1.1M
- HBNC 515.5K
- Earning Date
- DAWN 10-29-2025
- HBNC 10-22-2025
- Dividend Yield
- DAWN N/A
- HBNC 3.92%
- EPS Growth
- DAWN N/A
- HBNC 170.74
- EPS
- DAWN N/A
- HBNC 1.17
- Revenue
- DAWN $187,638,000.00
- HBNC $211,582,000.00
- Revenue This Year
- DAWN $12.56
- HBNC $47.63
- Revenue Next Year
- DAWN $48.02
- HBNC $4.03
- P/E Ratio
- DAWN N/A
- HBNC $13.97
- Revenue Growth
- DAWN 2190.50
- HBNC 19.27
- 52 Week Low
- DAWN $5.64
- HBNC $12.70
- 52 Week High
- DAWN $16.76
- HBNC $19.18
- Technical
- Relative Strength Index (RSI)
- DAWN 52.01
- HBNC 49.81
- Support Level
- DAWN $7.18
- HBNC $16.06
- Resistance Level
- DAWN $7.58
- HBNC $17.02
- Average True Range (ATR)
- DAWN 0.27
- HBNC 0.37
- MACD
- DAWN -0.03
- HBNC -0.05
- Stochastic Oscillator
- DAWN 33.92
- HBNC 44.18
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.